Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the adacolumn device in ulcerative colitis

Digestive Diseases and Sciences

Volumn 55, Issue 5, 2010, Pages 1421-1428

  Habermalz, Brigitte ^a   Sauerland, Stefan ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Apheresis; Meta analysis; Remission; Ulcerative colitis

Indexed keywords

METHYLPREDNISOLONE; PREDNISOLONE;

ARTICLE; BLOOD FILTER; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; ENDOSCOPY; HUMAN; INFLAMMATION; LEUKAPHERESIS; META ANALYSIS; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK FACTOR; STATISTICAL MODEL; STEROID THERAPY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; APHERESIS; GRANULOCYTE; INSTRUMENTATION; MONOCYTE; RANDOMIZED CONTROLLED TRIAL;

BLOOD COMPONENT REMOVAL; COLITIS, ULCERATIVE; GRANULOCYTES; HUMANS; MONOCYTES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953648808     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0845-x     Document Type: Article

References (28)

1. Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2007;41:874-888. (Pubitemid 350307073)
2. Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci. 2006;51:2031-2038. doi:10.1007/ s10620-006-9199-9209
3. Noguchi M, Hiwatashi N, Hayakawa T, Toyota T. Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease:role of bystander suppression. Ther Apher. 1998;2:109-114. doi:10.1111/j.1744-9987.1998.tb00086.x.
4. Saniabadi AR, Hanai H, Fukunaga K, et al. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci. 2007;37:191-200. doi:10.1016/j.transci.2007.08.003. (Pubitemid 350186259)
5. Saniabadi AR, Hanai H, Suzuki Y, et al. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171-184. doi:10.1002/jca. 20046.
6. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995;30:322-329. doi:10.1007/BF0234 7507.
7. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-linetreatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004;49:565-571. doi:10.1023/B:DDAS.0000026299.43792.ae. (Pubitemid 38992542)
8. Schwartz D, Ferguson JR. Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis. Curr Med Res Opin. 2007;23:2715-2728. doi:10.1185/030079907X233241. (Pubitemid 350146409)
9. Sauerland S, Seiler CM. Role of systematic reviews and metaanalysis in evidence-based medicine. World J Surg. 2005;29: 582-587. doi:10.1007/s00268-005- 7917-7. (Pubitemid 41187393)
10. Emmrich J, Petermann S, Nowak D, et al. Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis- results of a randomized pilot trial. Dig Dis Sci. 2007;52:2044-2053. doi:10.1007/s10620-006-9696-x. (Pubitemid 47246519)
11. Sawada K, Kusugami K, Suzuki Y, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol. 2005;100:1362-1369. doi:10.1111/j.1572- 0241.2005.41089.x.
12. Sawada K, Muto T, Shimoyama T, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des. 2003;9:307-321. doi:10.2174/1381612033391928. (Pubitemid 36131725)
13. Ricart E, Esteve M, Andreu M, et al. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: a pilot, prospective, multicenter, randomized study. World J Gastroenterol. 2007;13:2193-2197.
14. Sakuraba A, Sato T, Naganuma M, et al. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis foractive ulcerative colitis. J Gastroenterol. 2008;43:51-56. doi: 10.1007/s00535-007-2129-6. (Pubitemid 351324986)
15. Sands BE, Sandborn WJ, Feagan B, KLöfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S. A randomized, double-blind, sham-controlled study of granulocyte/ monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400-409.
16. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis. 2007;39:430-434. doi:10.1016/j.dld.2007.01.001. (Pubitemid 46506182)
17. Nakamura T, Kawagoe Y, Matsuda T, et al. Effect of granulocyte and monocyte adsorption apheresis on urinary albumin excretion and plasma endothelin-1 concentration in patients with active ulcerative colitis. Blood Purif. 2004;22:499-504. doi:10.1159/000081896. (Pubitemid 40069618)
18. Shimoyama T, Sawada K, Tanaka T, et al. Granulocyte and monocyte apheresis with the G-1 column in the treatment of patients with active ulcerative colitis. Jpn J Apher. 1999;18:117-131.
19. Hanai H, Iida T, Takeuchi K, et al. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: An unblinded randomised multicentre controlled study. Dig Liver Dis. 2008;40:433-440. doi: 10.1016/j.dld.2008.01.007.
20. Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci. 2002;47:2349-2353. doi:10.1023/A: 1020159932758. (Pubitemid 35205310)
21. Maiden LP, Baur R, Bjarnason I, et al. Maintaining remission of IBD by Adacolumn apheresis in those at risk of relapsing (abstract). Gastroenterology. 2007;132[Suppl 1]:A-503.
22. Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007; 132:516-526. doi:10.1053/j.gastro.2006.12.037.
23. Ljung T, Thomsen OO, Vatn M, et al. Granulocyte, monocyte/ macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol. 2007; 42:221-227. doi:10.1080/ 00365520600979369.
24. Takemoto K, Kato J, Kuriyama M, et al. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liver Dis. 2007;39:422-429. doi:10.1016/ j.dld.2007.01.010.
25. Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naive patients. Dig Liver Dis. 2008; 40(9):731-1716
26. Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36-44. doi:10.1159/000080079. (Pubitemid 39179238)
27. Ando T, Watanabe K, Furutta R, et al. Predictors of a response to cyclosporine or leukocyte removal therapy in patients with refractory ulcerative colitis. Dig Endosc. 2005;17:153-158. doi: 10.1111/j.1443-1661.2005.00494.x. (Pubitemid 40570102)
28. Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SPL. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials. 2007;8:17. doi:10.1186/1745- 6215-8-17.